Congenital Anomalies in Children of Mothers Taking Antiepileptic Drugs with and without Periconceptional High Dose Folic Acid Use: A Population-Based Cohort Study

Article English OPEN
Ban, Lu ; Fleming, Kate M ; Doyle, Pat ; Smeeth, Liam ; Hubbard, Richard B ; Fiaschi, Linda ; Tata, Laila J (2015)

BACKGROUND: Antenatal antiepileptic drug (AED) use has been found to be associated with increased major congenital anomaly (CA) risks. However whether such AED-associated risks were different according to periconceptional high dose (5mg daily) folic acid supplementation is still unclear. \ud \ud METHODS: We included 258,591 singleton live-born children of mothers aged 15-44 years in 1990-2013 from The Health Improvement Network, a large UK primary care database. We identified all major CAs according to the European Surveillance of Congenital Anomalies classification. Absolute risks and adjusted odds ratios (aOR) were calculated comparing children of mothers prescribed AEDs to those without such prescriptions, stratified by folic acid prescriptions around the time of conception (one month before conception to two months post-conception). \ud \ud RESULTS: CA risk was 476/10,000 in children of mothers with first trimester AEDs compared with 269/10,000 in those without AEDs equating to an aOR of 1.82, 95% confidence interval 1.30-2.56. The highest system-specific risks were for heart anomalies (198/10,000 and 79/10,000 respectively, aOR 2.49,1.47-4.21). Sodium valproate and lamotrigine were both associated with increased risks of any CA (aOR 2.63,1.46-4.74 and aOR 2.01,1.12-3.59 respectively) and system-specific risks. Stratification by folic acid supplementation did not show marked reductions in AED-associated risks (e.g. for CAs overall aOR 1.75, 1.01-3.03 in the high dose folic acid group and 1.94, 95%CI 1.21-3.13 in the low dose or no folic acid group); however, the majority of mothers taking AEDs only initiated high dose folic acid from the second month of pregnancy. \ud \ud CONCLUSIONS: Children of mothers with AEDs in the first trimester of pregnancy have a 2-fold increased risk of major CA compared to those unexposed. We found no evidence that prescribed high dose folic acid supplementation reduced such AED-associated risks. Although statistical power was limited, prescribing of folic acid too late for it to be effective during the organogenic period or selective prescribing to those with more severe morbidity may explain these findings.
  • References (48)
    48 references, page 1 of 5

    1. Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2 052 922 and age-specific fertility rates of women with epilepsy. The Lancet. 1998; 352: 1970-1973. doi: 10.1016/S0140-6736(98)04512-7

    2. Chen Y, Chiou H, Lin H, Lin H. Affect of seizures during gestation on pregnancy outcomes in women with epilepsy. Arch Neurol. 2009; 66: 979-984. doi: 10.1001/archneurol.2009.142 PMID: 19667219

    3. Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Research. 2008; 81: 1-13. doi: 10.1016/j.eplepsyres.2008.04.022 PMID: 18565732

    4. Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D, Arnon J, Ornoy A. Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs. 2008; 22: 325- 334. PMID: 18336060

    5. Jentink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. New England Journal of Medicine. 2010; 362: 2185-2193. doi: 10.1056/NEJMoa0907328 PMID: 20558369

    6. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. The Lancet Neurology. 2011; 10: 609-617. doi: 10.1016/S1474-4422(11)70107-7 PMID: 21652013

    7. Hernández-Díaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012; 78: 1692-1699. doi: 10.1212/WNL. 0b013e3182574f39 PMID: 22551726

    8. Mawhinney E, Campbell J, Craig J, Russell A, Smithson W, Parsons L, et al. Valproate and the risk for congenital malformations: Is formulation and dosage regime important? Seizure. 2012; 21: 215-218. doi: 10.1016/j.seizure.2012.01.005 PMID: 22364656

    9. Vajda FJO'Brien TJ, Graham JE, Lander CM, Eadie MJ. Dose dependence of fetal malformations associated with valproate. Neurology. 2013; 81: 999-1003. doi: 10.1212/WNL.0b013e3182a43e81 PMID: 23911758

    10. NICE. CG137 Epilepsy: full guideline. In: NICE [Internet]. Available: http://www.nice.org.uk/. Accessed 17 May 2013.

  • Related Research Results (1)
  • Similar Research Results (1)
  • Metrics
    No metrics available
Share - Bookmark